ImaginAb is able to provide its CD8 technology through a non-exclusive license agreement to pharmaceutical and biotech businesses for use in therapeutic clinical development programs.
Over the last 4 years, in addition to a multi-party collaboration agreement with AstraZeneca, Pfizer and Takeda Pharmaceutical Company to focus on furthering the clinical development of ImaginAb’s CD8 ImmunoPET technology, we have also entered in to numerous non-exclusive licence agreements with some of the largest pharmaceutical and biotech business to provide our technology to support their clinical development programs.
Find out moreOur Business Development Team would welcome the opportunity to talk to pharmaceutical and biotech businesses interested in using our CD8 technology in their therapeutic clinical development program.
In the last 3 years, we have extended our operations so that we can offer clinical trials within the US, Europe and Australia.
We’re here to help at every stage with implementation support and operations imaging protocols ICF, IND, IRB and user training.
Our team are established industry experts, made up of commercial and operational leaders from the pharmaceutical, biotech and radiopharmaceuticals industries.
We have an extensive network of ImmunoPET Imaging sites, validated and trained for our unique CD8 imaging technology.
Whether a clinician, commercial organization or patient, find our network of clinical trials listed below.
In the last 3 years we have extended our operations and can offer clinical trials within the US, Europe, and Australia.
View all clinical trials
